Adjuvant immunotherapy with bacillus Calmette-Guérin in prostatic cancer

P. Guinan, G. Baumgartner, E. Totonchi, T. John, R. Crispen, R. Rao, R. Ablin

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Ninety-two patients with histologically proved prostatic cancer were studied. Forty-six patients were treated with bacillus Calmette-Guerin (BCG) adjuvant immunotherapy, and 46 other patients, matched for stage and hormone therapy, served as controls. Survival from the time of histologic diagnosis was sixteen and one-half months longer (thirty-seven and one-half versus twenty-one months) in the BCG-treated patients. There was no mortality and only minimal morbidity. Changes in some immunologic parameters (white blood cell count, skin tests) suggest an immune response.

Original languageEnglish (US)
Pages (from-to)561-565
Number of pages5
Issue number6
StatePublished - Dec 1979
Externally publishedYes

ASJC Scopus subject areas

  • Urology

Cite this